The Phase II trial results, published in Lancet Oncology, evaluated the likelihood of breast cancer returning in patients who are in complete remission after receiving chemotherapy and radiation without surgery.
Each of the 31 patients followed had a complete response to chemotherapy and none had a breast tumour recurrence after a median follow-up of 26.4 months.
Nullam et interdum sapien, eu facilisis erat. Etiam eget quam nisi. Integer imperdiet eros vel lorem pellentesque, non ornare libero aliquam. Phasellus nec urna molestie, pellentesque nisi at, volutpat odio. Mauris pulvinar efficitur neque at pretium. Nunc euismod turpis ante, et porttitor diam auctor sed. Ut erat metus, tincidunt a malesuada nec, blandit ut felis. Nullam pulvinar ac dolor at euismod. Curabitur scelerisque ac urna in cursus. Nulla nisi elit, consectetur a sem ac, laoreet condimentum massa
